Evidence map›Paper›PMID 36439492›Full record

ArticleFrontiers in oncology2022

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma.

Thorben Fründt, Johann von Felden, Jenny Krause, Asmus Heumann, Jun Li, Sabine Riethdorf, Klaus Pantel, Samuel Huber, Ansgar W Lohse, Henning Wege and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Thorben FründtDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johann von FeldenDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jenny KrauseDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Asmus HeumannDepartment of General, Visceral and Thorax Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jun LiDepartment of General, Visceral and Thorax Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Sabine RiethdorfInstitute of Tumorbiology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
Klaus PantelInstitute of Tumorbiology, University Medical Center Hamburg- Eppendorf, Hamburg, Germany.
Samuel HuberDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ansgar W LohseDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Henning WegeDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kornelius SchulzeDepartment of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Universität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DEKlinikum Esslingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is an aggressive tumor associated with a high rate of recurrence after resection. An important risk factor for recurrence is the presence of occult metasta-ses, which are not radiologically detectable at the time of diagnosis. There are currently no biomarkers for the preoperative assessment of micrometastases. A previous study demonstrated the prognostic relevance of circulating tumor cells (CTC) in patients with advanced CCA but the potential of CTCs as a preoperative marker for detecting occult metastases has not been investigated so far. In this two-phase study, we first recruited a cohort of 27 patients with histologically proven, metastatic CCA or gallbladder cancer (GBCA) to assess feasibility (feasibility cohort, FC). CTCs were measured in the peripheral blood using the CellSearch System (CSS) between October 2012 and January 2017. Subsequently, in 11 patients undergoing curative-intended resection for CCA (intrahepatic CCA: n =4; extrahepatic CCA n= 6; gallbladder cancer: n=1), peripheral and central venous blood specimens were obtained to improve detection rate by simultaneous measurement and to elucidate distribution of CTCs in different venous compartments. Presence of CTCs detection was correlated with postoperative TNM-status. In the FC, CTCs (range 1-3 cells, median: 1) were detected in 40% (11/27) patients and were signifi-cantly associated with worse overall survival (hazard ratio: 3.59; 95% CI: 1.79- 7.1; p = 0.04). By combined peripheral and central measurement, CTC detection was increased to 54% (6/11) in the resection cohort (RC) and was associated with metastases that were only identified during the surgical procedure (peritoneal carcinoma: n = 1; infiltration of the duodenum: n = 1) or immediately after surgery (evidence of pulmonary metastases by CT scan two days after resection, not evident on initial tumor staging prior resection). Taken together, in this single center pilot study, we demonstrated that CTCs are detectable in CCA patients and are associated with significantly impaired survival in patients at metastatic stage. Detection rate prior to surgery was improved to >50% by combined peripheral and central measurement. Moreover, preoperative CTC detection may indicate existing metastases and could help to stratify patients more accurately.

Indexed as

cellsearch systemcholangiocarcinomacirculating tumor cellsliquid biopsyoccult metastases

Identifiers

PMID36439492
PMCPMC9685781
OpenAlexW4308878362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.